About the Program:
Target Audience:
This activity is intended for physicians, physician assistants, advanced practice nurses, general practitioners and other health care professionals involved in the treatment and management of patients who have or are at risk of HIV infection.
Program Objectives:
Upon completion of the program, participants should be able to:
-
Utilize current and emerging HIV therapies and treatment paradigms to improve their treatment of HIV-positive patients
- Evaluate and apply criteria for evaluating current and emerging HIV therapies and treatment paradigms
- Assess and discuss the latest data on HIV therapies and treatment paradigms
- Compare and contrast major ARV guidelines recommendations with emerging HIV therapies and treatment paradigms and discuss the relative advantages and disadvantages
- Discuss future directions in HIV treatment and research
Release Date: July 25, 2019
Expiration Date: July 25, 2020
Estimated time to complete each Module: 45 minutes per module
Media: Web
Faculty:
Eric Daar, MD (Co-Director)
Interim Chair, Department of Medicine
Chief, Division of HIV Medicine Harbor-UCLA Medical Center
Professor of Medicine,
David Geffen School of Medicine at UCLA
Los Angeles, CA
Joseph Eron, MD (Co-Director)
Professor of Medicine, School of Medicine Chief
Division of Infectious Diseases
The University of North Carolina at Chapel Hill
Chapel Hill, North Carolina
W. David Hardy, MD
Adjunct Professor of Medicine
Division of Infectious Diseases
Johns Hopkins University School of Medicine
Washington, DC
Helena Kwakwa, MD, MPH
Director HIV Clinical Services
Philadelphia Department of Public Health
Ambulatory Health Services
Philadelphia, Pennsylvania
Renslow Sherer, MD
Professor
of Medicine
Section
of Infectious Diseases and Global Health
University
of Chicago
Chicago,
Illinois
Pablo Tebas, MD
Professor of Medicine Hospital of the University of Pennsylvania
Director, Adult AIDS Clinical Trials Unit (ACTU)
Perelman School of Medicine at the University of Pennsylvania
Philadelphia, Pennsylvania
Back to Top
Accreditation Statement:
|
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of The University of Chicago Pritzker School of Medicine and ViralEd, Inc. The University of Chicago Pritzker School of Medicine is accredited by the ACCME to provide continuing medical education for physicians
|
Back to Top
Credit Designation:
Module 1 (Choosing ART to Optimize Patient Outcomes):
The University of Chicago Pritzker School of Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Module 2 (Recent Data on HIV Therapies and Treatment Paradigms):
The University of Chicago Pritzker School of Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Module 3 (ART Choices when Guideline Recommendations Differ or are Incomplete):
The University of Chicago Pritzker School of Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Module 4 (Future Direction in HIV Treatment and Research):
The University of Chicago Pritzker School of Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Back to Top
Disclosure of Conflicts of Interest:
As a
provider accredited by the ACCME, The University of Chicago Pritzker School of
Medicine, requires everyone who is in a position to control the content of an
education activity to disclose all relevant financial relationships with any
commercial interest. This includes any entity producing, marketing, re-selling,
or distributing health care goods or services consumed by, or used on,
patients. The ACCME defines "relevant financial relationships" as
financial relationships in any amount, occurring within the past 12 months,
including financial relationships of a spouse or life partner that could create
a conflict of interest. Mechanisms are in place to identify and resolve any
potential conflict of interest prior to the start of the activity.
Additionally,
The University of Chicago Pritzker School of Medicine requires authors to
identify investigational products or off-label uses of products regulated by
the US Food and Drug Administration at first mention and where appropriate in
the content.
Eric Daar, MD
•Consulting Fees: Gilead
•Grant Support: Gilead, Merck, ViiV
Joseph Eron, MD
•Consulting Fees: Gilead, ViiV, Janssen, Merck
•Contracted Research: Gilead, ViiV, Janssen
W. David Hardy, MD
•Advisory Board: Gilead, Merck, ViiV, CSL-Behring (Calimmune), Enochian
•Research Support: Gilead, Janssen, Merck ViiV
Helena Kwakwa, MD
•Nothing to Disclose
Renslow Sherer, MD
•Nothing to Disclose
Pablo Tebas, MD
•Consulting Fees: Merck, Gilead, ViiV
•Royalty: UpToDate
University of Chicago Center for
Continuing Medical Education and ViralEd, Inc Declarations
The staff of the
Center for Continuing Medical Education and Viral Ed Inc. have no financial
relationships to disclose.
Back to Top
Disclaimer:
The views expressed in this activity are
those of the individual speaker. It should not be inferred or assumed that they
are expressing the views of any pharmaceutical or product/device manufacturer,
provider of commercial services, or The University of Chicago. The drug
selection and dosage information presented in this activity are believed to be
accurate. However, participants are urged to consult the full prescribing
information on any agent(s) presented in this activity for recommended dosage,
indications, contraindications, warnings, precautions, and adverse effects
before prescribing any medication. This is particularly important when a drug
is new or infrequently prescribed.
Copyright © 2020 University of Chicago.
All rights reserved including translation into other languages. No part of this
activity may be reproduced or transmitted in any form or by any means,
electronic or mechanical, including photocopying, recording, or any information
storage and retrieval systems, without permission in writing from The
University of Chicago Center for Continuing Medical Education.
Back to Top
Computer System Requirements:
This
program requires a modern web browser (Internet Explorer 7+, Mozilla
Firefox, Apple Safari, Google Chrome). Certain educational activities
may require additional software to view multimedia, presentation, or
printable version of their content. These activities will be marked as
such and will provide links to the required software. That software may
be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint,
Windows Media Player and Real Networks Real One Player.
Back to Top
·
For CME Accreditation Questions, please click HERE
This activity is supported by an independent educational grant from ViiV Healthcare.
Jointly provided by the University of Chicago Pritzker School of Medicine and ViralEd, Inc.
|